Does the number of embryos loaded on a single cryo-carrier affect post-vitrification survival rate? 
Post-thawing survival rate following vitrification is affected by the number of embryos per single cryo-carrier undergoing the vitrification equilibration phase, with the optimum number of three cleaved embryos or one blastocyst per single cryo-carrier. Further studies are required to determine the optimum number of cleaved embryos or blastocysts that should be loaded onto a single cryo-carrier vitrification device.
Artificial intelligence in the IVF laboratory: overview through the application of different types of algorithms for the classification of reproductiv 
Routine use of AI in assisted reproduction clinics is just a matter of time. However, the choice of AI technique to be used is supported by a better understanding of the principles subjacent to each technique, that is, its robustness, pros, and cons. We provide some current (although incipient) and potential uses of AI on the clinic routine, discussing how accurate and friendly it could be. Finally, we propose some standards for AI research on th
Performance of a deep learning based neural network in the selection of human blastocysts for implantation 
Here, we evaluated the use of a deep convolutional neural network (CNN), trained using single timepoint images of embryos collected at 113 hr post-insemination, in embryo selection amongst 97 clinical patient cohorts (742 embryos) and observed an accuracy of 90% in choosing the highest quality embryo available.
ai/modelling/artificial intelligence, deep learning and ivf/
Do human embryos have the ability of self-correction? 
Of the 9 euploid blastocysts, four showed euploid debris, while in the others, the debris were aneuploid. In the remaining pairs, the debris showed additional aneuploidy to those presented by their corresponding blastocyst. The observed ability of human embryos to self-correction doubts many invasive and non-invasive preimplantation testing for aneuploidy at the blastocyst stage, rendering high rate of false positive (discarding "good" embryos)
Surgically Extracted Epididymal Sperm from Men with Obstructive Azoospermia Results in Similar IVF/ICSI Outcomes Compared with Normal Ejaculated Sperm 
For couples with a male partner with OA, epididymal sperm IVF/ICSI outcomes compare similarly with age-matched controls undergoing IVF/ICSI using normal, ejaculated sperm. These results may help reproductive surgeons provide reassurance about the use of obstructed epididymal sperm as well as help guide discussions about anticipated outcomes of IVF/ICSI.
follicular fluid/amh/follicular fluid and ivf outcomes/
The duration of embryo culture after mouse IVF differentially affects cardiovascular and metabolic health in male offspring 
Using a mouse model, we demonstrate that in male but not female offspring, adverse cardiovascular (CV) health was more likely with prolonged culture to the blastocyst stage, but metabolic dysfunction was more likely if embryo transfer (ET) occurred at the early cleavage stage.
Pregnancy and Lactation in a 67-Year-Old Elderly Gravida following Donor Oocyte In Vitro Fertilization 
This case represents the eldest gravidae identified in the literature and illustrates the potential for a relatively uncomplicated perinatal course with successful lactation. This case may enable other providers to counsel elderly patients on anticipated outcomes inclusive of ability to breastfeed.
Characteristics of the IVF Cycle that Contribute to the Incidence of Mosaicism 
With the use of a proprietary algorithm for automated diagnosis of aneuploidy and mosaicism, we retrospectively analyzed a large series of 115,368 trophectoderm biopsies from 27,436 PGT-A cycles to determine whether certain biological factors and in vitro fertilization (IVF) practices influence the incidence of overall aneuploidy, whole uniform aneuploidy, mosaicism, and TE biopsies with only segmental aneuploidy
Normalized Ploidy Following 20 Consecutive Blastocysts with Chromosomal Error: Healthy 46, XY Pregnancy with IVF after Intraovarian Injection of Autol 
It appears that intraovarian application of autologous platelet-derived growth factors, when used before IVF, can impact oocyte integrity and facilitate euploid blastocyst development. Although research on intraovarian injection of autologous activated platelet rich plasma has already shown improved quantitative IVF responses, this is the first description of qualitative improvements in embryo genetics after intraovarian injection of autologous p
Mechanisms of human embryo development: from cell fate to tissue shape and back 
Here, I discuss the evidence that supports a role for the crosstalk between cell fate and tissue shape during early human embryogenesis. This is a critical developmental period, when the body plan is laid out and many pregnancies fail
Correlation between aneuploidy, standard morphology evaluation and morphokinetic development in 1730 biopsied blastocysts: a consecutive case series s 
Correlations were observed, in that euploid human blastocysts showed a higher percentage with top quality inner cell mass (ICM) and trophectoderm (TE), higher expansion grades and shorter time to start of blastulation, expansion and hatching, compared to aneuploid ones.
Women could conceive after ovarian tumors, study shows 
Women receiving fertility-sparing surgery for treatment of borderline ovarian tumours were able to have children, a study from Karolinska Institutet in Sweden published in Fertility & Sterility shows. Natural fertility was preserved in most of them and only a small proportion required assisted reproductive treatment such as in vitro fertilization. Survival in the group was also as high as in women who had undergone radical surgical for treatment
Noninvasive preimplantation genetic testing for aneuploidies (niPGT-A) and the principle of primum non nocere 
Perhaps with the intention of obtaining larger amounts of free-DNA, some groups are routinely postponing and establishing free-DNA collection in culture medium for Noninvasive preimplantation genetic testing for aneuploidies (niPGT-A) to day 6 for all blastocysts.